Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 2, 2015, Pages 288-292

  Haines, Hilary L ^a   Bleesing, Jack J ^b   Davies, Stella M ^b   Hornung, Lindsey ^b   Jordan, Michael B ^b   Marsh, Rebecca A ^b   Filipovich, Alexandra H ^b  

^a University of Alabama at Birmingham   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Donor lymphocyte infusion (DLI); Mixed donor chimerism; Nonmalignant disease; Pediatrics; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; MELPHALAN; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DONOR; DONOR LYMPHOCYTE INFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIXED DONOR CHIMERISM; OUTCOME ASSESSMENT; REDUCED INTENSITY CONDITIONING; SIBLING; ADOLESCENT; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; IMMUNOLOGY; INFANT; LYMPHOCYTE TRANSFUSION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MUCOPOLYSACCHARIDOSES; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; CHIMERISM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE TRANSFUSION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MELPHALAN; MUCOPOLYSACCHARIDOSES; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS; VIDARABINE;

EID: 84920903706     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.010     Document Type: Article

References (18)

1. Hill R.S., Petersen F.B., Storb R., et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986, 67:811-816.
2. Mattsson J., Uzunel M., Remberger M., Ringden O. Tcell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001, 71:433-439.
3. Meyer R.G., Wagner E.M., Konur A., et al. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation. Bone Marrow Transplant 2010, 45:668-674.
4. Svenberg P., Mattsson J., Ringden O., Uzunel M. Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism. Bone Marrow Transplant 2009, 44:757-763.
5. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009, 50:1809-1817.
6. Marsh R.A., Vaughn G., Kim M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116:5824-5831.
7. Peters C., Steward C.G. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003, 31:229-239.
8. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006, 107:1233-1236.
9. Krishnamurti L., Kharbanda S., Biernacki M.A., et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008, 14:1270-1278.
10. Frugnoli I., Cappelli B., Chiesa R., et al. Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia. Bone Marrow Transplant 2010, 45:1047-1051.
11. Gorczynska E., Turkiewicz D., Toporski J., et al. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children. Bone Marrow Transplant 2004, 33:211-217.
12. Hongeng S., Pakakasama S., Benjaponpitak S., et al. Donor lymphocyte infusion can eliminate mixed chimerism in nonmyeloablative stem cell transplantation for correction of hyper-IgM syndrome. Acta Haematol 2005, 114:174-176.
13. Yoshimi A., Bader P., Matthes-Martin S., et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005, 19:971-977.
14. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
16. Breuer S., Preuner S., Fritsch G., et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 2012, 26:509-519.
17. Saito B., Fukuda T., Yokoyama H., et al. Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen. Biol Blood Marrow Transplant 2008, 14:1148-1155.
18. Marsh R.A., Kim M.O., Liu C., et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant 2013, 19:1625-1631.